Evidence map›Paper›PMID 42879153›Full record

ArticleJAMA network open2026

Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer.

Varun Nandakumar, Yeonjung Jo, Micah Ostrowski, Georges Gebrael, Zeynep Irem Ozay, Edwin Lin, Krishnam Goel, Rachel Revillo, Laxmi Upadhyay, Tejita Agarwal and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Varun NandakumarDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Yeonjung JoCancer Biostatistics, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Micah OstrowskiDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Georges GebraelDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Zeynep Irem OzayDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Edwin LinDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Krishnam GoelDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Rachel RevilloDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Laxmi UpadhyayDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Tejita AgarwalDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Nicolas SayeghDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
Vinay Mathew ThomasDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Haoran LiDivision of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood.
Neeraj AgarwalDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.
Umang SwamiDivision of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) is a targeted radioligand therapy approved for patients with metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer after progression on androgen receptor pathway inhibitors (ARPIs). Data to guide treatment sequencing are limited. Objective: To evaluate survival outcomes in patients with mAPMR prostate cancer receiving Lu-177 PSMA by line of therapy and the timing of taxane exposure. Design, Setting, and Participants: This cohort study used a deidentified electronic health record research database to obtain comprehensive longitudinal oncology data from community and academic practices across the US. Among patients with metastatic prostate cancer in the dataset, those who received Lu-177 PSMA after an ARPI between December 19, 2018, and June 23, 2025, met the inclusion criteria. The data cutoff was June 30, 2025. Exposure: Receipt of Lu-177 PSMA, stratified by line of therapy and timing of taxane exposure (before Lu-177 PSMA, after Lu-177 PSMA, or never received taxane). Main Outcomes and Measures: Primary end points were clinical time to next treatment (TTNT; defined as the time from Lu-177 PSMA initiation to next systemic therapy or death) and clinical overall survival (OS; defined as the time from Lu-177 PSMA initiation to death). Both outcomes were censored at last follow-up and estimated using the Kaplan-Meier method with 95% CIs. Results: Among the 850 patients included, the median (IQR) age was 74 (68-80) years; most were treated in community settings (598 [70.4%]) and had commercial insurance (520 [61.2%]). A total of 466 patients (54.8%) received taxane before Lu-177 PSMA, 35 (4.1%) received taxane after Lu-177 PSMA, and 349 (41.1%) never received taxane. Median clinical TTNT and clinical OS with Lu-177 PSMA were 8.0 (95% CI, 7.4-9.0) months and 12.0 (95% CI, 11.0-13.0) months for patients with taxane exposure before Lu-177 PSMA; 10.0 (95% CI, 9.2-11.0) months and 14.0 (95% CI, 13.0-17.0) months for patients who never received taxane; and 6.0 (95% CI, 4.9-8.0) months and 16.0 (95% CI, 13.0-not reached) months for patients with taxane exposure after Lu-177 PSMA, respectively. Conclusions and Relevance: In this cohort study, outcomes with Lu-177 PSMA were broadly consistent across treatment lines and taxane sequencing groups. These findings may help inform patient counseling, although prospective studies are needed to determine the optimal treatment sequencing strategy.

Indexed as

Bridged-Ring CompoundsLutetiumProstatic NeoplasmsRadioisotopesTaxoidsAgedAged, 80 and overAntigens, SurfaceCohort StudiesGlutamate Carboxypeptidase IIHumansMaleMiddle AgedTreatment OutcomeAntigens, SurfaceBridged-Ring CompoundsGlutamate Carboxypeptidase IILutetiumLutetium-177RadioisotopestaxaneTaxoids

Identifiers

PMID42879153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.